Lausanne, Switzerland, July 8th 2020 — Ormendes SA is proud to announce that Sivomixx®800, one of its probiotic formulations has been used in a clinical study to supplement Covid-19 patients in addition to their standard care, the results of which have now been published in Frontiers in Medicine.
Bacteriotherapy in addition to anti-inflammatory, antibiotics, or monoclonal antibody may improve outcomes for COVID-19 patients, a study from Italy has found.
Diarrhea and other gastrointestinal problems are common symptoms of COVID-19. The cells in the gut (enterocytes) may harbor the virus, acting as a reservoir of infection, according to Chinese researchers (2).
This prompted researchers at “Sapienza” University to start an independent study on 70 patients hospitalized at Policlinico Umberto I, Roma (Italy) who had tested positive for COVID-19 and required oxygen treatment but did not need ventilators at the time of admission. In addition to the current anti-COVID-19 treatment, a probiotic formulation (Sivomixx®800) was administered to 28 subjects, aiming to enhance the production of molecules with antiviral activity.
- Within three days, nearly all patients supplemented with bacteriotherapy showed remission of diarrhea and other symptoms, compared to less than half in the non-supplemented group.
- In patients receiving oral bacteriotherapy, the estimated risk of developing respiratory failure was eight-fold lower compared to the group which was not supplemented.
Dr. Giancarlo Ceccarelli M.D. Ph.D, one of the study investigators says:
“Our preliminary results evidenced an improved survival rate and a lower risk of transfer to an intensive resuscitation for patients supplemented with the probiotic compared with those on standard treatment only. The gut bacteria have a long-reaching immune impact on the pulmonary immune system. Our results stress the importance of the gut-lung axis in the control of the COVID-19 illness. Bacteriotherapy could represent an additional option for this severe disease. As a note of caution, I want to stress that our study results are preliminary and specific for this product.”
The study was published in Frontiers in Medicine (1). The data from this independent study are preliminary and will need to be confirmed by more extensive trials.
Mr. Orlando, CEO of Ormendes SA, says: “I am very pleased that one of our promising formulations has been selected as part of this independent study. It confirms the growing awareness by the scientific community of the key role of microbiota in addressing healthcare today.”
About the study
This independent study was conducted at the Policlinico Umberto I Hospital in Rome on 70 Covid-19 positive patients enrolled between March 9 and April 4, 2020. Ormendes SA supplied the free product necessary for the completion of the study and was not involved in the design or elaboration of the study itself.
SivoMixx®800 is a food supplement containing different strains of lactic acid bacteria and bifidobacteria at a concentration of 800 billion CFU (Colony Forming Units) per sachet. It is not intended to treat, prevent, or cure any disease.
More information at www.sivomixx800.com
Ormendes SA, very high quality and heavy concentration microbiotics
Ormendes SA is a Swiss bio-tech company specialized in the development and distribution of high quality and heavy concentration microbiotics, believing in the potential of oral bacteriotherapy for human health. More information at www.ormendes.ch
- D’Ettorre et al. Challenges in the management of SARS-CoV2 infection: the role of oral bacteriotherapy as complementary therapeutic strategy to avoid the progression of COVID-19. Front. Med. 2020 7:389. doi: 10.3389/fmed.2020.00389
- Feng, Z.; Wang, Y.; Qi, W. The Small Intestine, an Underestimated Site of SARS-CoV-2 Infection: From Red Queen Effect to Probiotics. Preprints2020, 2020030161 (doi: 10.20944/preprints202003.0161.v1)
Florence Pryen, Managing Director +41 (0)79 640 75 20